Drug Pricing & Negotiation
Expert articles and analysis related to drug pricing & negotiation.
AI Summary — Last 30 Days
In the past 30 days, the Trump administration's drug pricing strategies, particularly the most-favored nation (MFN) deals with 16 pharmaceutical companies, are set to phase out, potentially affecting pricing dynamics in the U.S. market as this could lead to increased costs for patients and payers alike, especially as the administration pushes for higher drug prices in Europe to subsidize U.S. expenditures. Meanwhile, constrained state budgets are prompting programs like Ryan White to restrict access to essential treatments, such as those for HIV, which could exacerbate health disparities among vulnerable populations (KFF). Additionally, policy shifts and leadership changes within organizations like Elevance underscore the ongoing transformation within health benefits management amidst a backdrop of rising pharmaceutical costs (Healthcare Finance News).
Related Articles
STAT+: Minnesota report shows large hospitals continue to dominate the 340B drug discount program
Minnesota hospitals and clinics participating in a controversial U.S. drug discount program reaped at least $1.34 billion in revenue in 2024.
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
SEC filings show that, at least for some drugmakers, "most-favored nation" drug pricing deals with President Trump last three years.
As Drug Pricing Grows More Complex, Scripta Offers Comparison Tools: Eric Levin
He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t.
Diagnosed with an autoimmune disorder, a California man was prescribed a drug that costs thousands of dollars a month. He said he was reassured that the drugmaker’s copay card would cover his share, b...
STAT+: Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program
DOJ is backing AbbVie in its battle to overturn a Colorado law that prohibits pharmaceutical companies from placing restrictions on the 340B drug discount program.
STAT+: Cigna, extending reach into prescription drugs, acquires major pharmacy used by hospitals
Scoop: Cigna has acquired CarepathRx, a large pharmacy backed by private equity that dispenses prescription drugs to nearly 10% of U.S. hospitals.
Trump calls on Congress to codify Most-Favored-Nation framework
In a record-long State of the Union speech Tuesday night, President Donald Trump spent less than five minutes talking about healthcare.In that time, he addressed the "crushing cost of healthcare."Trum...
STAT+: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more
In his State of the Union address, President Trump claimed he had brought U.S. prescription drug costs from the highest in the world to the lowest
White Paper: FQHC 340B Contract Pharmacies and Medicare HIV Drug Access
Download the white paper. Background The 340B Drug Pricing Program is a federal program that requires drug manufacturers to sell prescription drugs at discounted prices to certain healthcare facilitie...
STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Will Novo Nordisk’s slashing of obesity drug prices save patients’ money or expand access? It depends.